Bispecific antibodies for cancer therapy

Jean-Charles Soria shared a post on LinkedIn about a recent paper by Christian Klein et al. published in Nature Reviews Drug Discovery.

“The present and future of bispecific antibodies for cancer therapy”

Authors: Christian Klein, Ulrich Brinkmann, Janice Reichert and Roland Kontermann

“Bispecific antibodies (bsAbs) allow therapeutic applications that cannot be achieved using conventional antibodies. There are 14 bsAbs approved: 11 for cancer and 3 for non-oncology indications.

This review summarizes this very active field, including bsAb signaling pathway modulators, tumor-targeted receptor agonists, ADC, bispecific T cell, natural killer cell and checkpoint inhibitors.”

Source: Jean-Charles Soria/LinkedIn

Jean-Charles Soria serves as Amgen’s senior vice president of Oncology within Global Development. He is a medical oncologist and a professor of medicine at Paris-Saclay University. From 2017 to 2019, he was the senior vice president of Research and Development in Oncology at AstraZeneca. Additionally, Soria has authored or co-authored over 670 articles in leading international journals and has been recognized as one of the world’s most influential research scientists.